-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Zevra Therapeutics, Raises Price Target to $27

Benzinga·06/09/2026 17:13:52
Listen to the news
BTIG analyst Kambiz Yazdi reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $27.